- Conditions
- HIV-1-infection
- Interventions
- GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 42 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 13,063
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fever, Wheezing
- Interventions
- text message
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • New York, New York
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Rifabutin
- Drug
- Lead sponsor
- Pharmacia
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 33
- States / cities
- Irvine, California • Sylmar, California • Denver, Colorado + 22 more
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Carfilzomib, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 22
- States / cities
- Oakland, California • Orange, California • Aurora, Colorado + 19 more
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo
- Biological · Other
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 6 Months to 11 Years
- Enrollment
- 3,600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 47
- States / cities
- Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more
- Conditions
- Quality of Life, Breakthrough Cancer Pain
- Interventions
- Fentanyl
- Drug
- Lead sponsor
- Galena Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 36
- States / cities
- Mobile, Alabama • Peoria, Arizona • Scottsdale, Arizona + 30 more
- Conditions
- Coronary Disease, Diabetes Mellitus
- Interventions
- torcetrapib/atorvastatin, atorvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 15,067 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 95
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Gilbert, Arizona + 92 more
- Conditions
- Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection
- Interventions
- imiquimod, fluorouracil, questionnaire administration, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 21 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Atlanta, Georgia + 6 more
- Conditions
- Androgenetic Alopecia, AGA, Male Pattern Baldness
- Interventions
- VDPHL01, Placebo
- Drug
- Lead sponsor
- Veradermics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 41 more
- Conditions
- Focal Epilepsy, Temporal Lobe Epilepsy, Medically Refractory Epilepsy, Memory Disorders, Epilepsy Comorbidities, Epilepsy Intractable, Epilepsy Surgery, Epilepsy, Temporal Lobe, Memory Deficits, Memory Disorder, Spatial, Memory Dysfunction, Spatial Perception
- Interventions
- Virtual Tour Recognition Memory Task, Intracranial EEG Recording with Research Electrodes (Aim III only), MRI Neuroimaging and Neuropsychological Assessment (Aim I)
- Behavioral · Device · Diagnostic Test
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Sacramento, California • Atlanta, Georgia
- Conditions
- Chronic Total Occlusion
- Interventions
- CTO Crossing and Percutaneous transluminal angioplasty
- Device
- Lead sponsor
- BridgePoint Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • Torrance, California + 7 more
- Conditions
- Plaque Psoriasis
- Interventions
- Secukinumab, Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 15
- States / cities
- Hot Springs, Arkansas • Los Angeles, California • Santa Ana, California + 11 more
- Conditions
- Episodic Migraine Headache
- Interventions
- LBR-101 High Dose, LBR-101 Low Dose, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 63
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more
- Conditions
- Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary
- Interventions
- Tazemetostat
- Drug
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Elagolix, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Mobile, Alabama • San Diego, California + 43 more
- Conditions
- Pemphigus Vulgaris (PV)
- Interventions
- Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 2 more
- Conditions
- Aortic Valve Stenosis
- Interventions
- TAVR with CENTERA THV
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Stanford, California • Loveland, Colorado + 19 more
- Conditions
- Human Immunodeficiency Virus
- Interventions
- No Marginal Cost Interventions, Low-Marginal Cost Interventions, Standard of Care
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 223,165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infections
- Interventions
- Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1995
- U.S. locations
- 49
- States / cities
- Long Beach, California • Los Angeles, California • Oakland, California + 33 more
- Conditions
- Complex Cardiovascular Surgery With Cardiopulmonary Bypass
- Interventions
- BE1116, FFP
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 12 more
- Conditions
- Autoimmune Pulmonary Alveolar Proteinosis
- Interventions
- Molgramostim, Placebo, Molgramostim Open-label
- Drug
- Lead sponsor
- Savara Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 13 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Bleximenib, Cytarabine, Daunorubicin or Idarubicin, Placebo
- Drug
- Lead sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Orlando, Florida + 10 more
- Conditions
- Type 1 Diabetes Mellitus, Multiple Sclerosis, Arthritis, Rheumatoid, Crohn's Disease, Psoriasis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 60 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Atlanta, Georgia • Manhasset, New York + 3 more
- Conditions
- Postoperative Pain, Acute
- Interventions
- PF614 capsule, Placebo
- Drug
- Lead sponsor
- Ensysce Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Houston, Texas • Salt Lake City, Utah